Response to Comments on "Aberrant type 1 immunity drives susceptibility to mucosal fungal infections".
Break TJ, Oikonomou V, Dutzan N, Desai JV, Swidergall M, Freiwald T, Chauss D, Harrison OJ, Alejo J, Williams DW, Pittaluga S, Lee CR, Bouladoux N, Swamydas M, Hoffman KW, Greenwell-Wild T, Bruno VM, Rosen LB, Lwin W, Renteria A, Pontejo SM, Shannon JP, Myles IA, Olbrich P, Ferré EMN, Schmitt M, Martin D; Genomics and Computational Biology Core16; Barber DL, Solis NV, Notarangelo LD, Serreze DV, Matsumoto M, Hickman HD, Murphy PM, Anderson MS, Lim JK, Holland SM, Filler SG, Afzali B, Belkaid Y, Moutsopoulos NM, Lionakis MS.
Break TJ, et al. Among authors: pontejo sm.
Science. 2021 Sep 17;373(6561):eabi8835. doi: 10.1126/science.abi8835. Epub 2021 Sep 16.
Science. 2021.
PMID: 34529475
Free PMC article.